MARKET REPORT

Multiple Myeloma: Update Bulletin #2

Multiple Myeloma: Update Bulletin #2

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.
We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Multiple Myeloma: Update Bulletin #2

This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM) market. Topics covered include; Amgen's announcement of top-line results of the Phase III A.R.R.O.W. trial for carfilzomib (Kyprolis) administered once-weekly at the 70 mg/m2 dose with dexamethasone in rrMM patients; FDA's partial clinical hold suspending patient recruitment in three studies of BMS' nivolumab (Opdivo)-based combinations in rrMM: CheckMate-602, CheckMate-039 and CA204142; and BioLineRx's regulatory filings tolaunch the Phase III GENESIS trial for BL-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in MM patients

Business Questions:

How do experts view Amgen's top-line results for the Phase III A.R.R.O.W. trial?

How do KOLs view the results for the higher dose carfilzomib (Kyprolis) and will it impact prescribing of bortezomib (Velcade) and ixazomib (Ninlaro)?

What do experts say about potential increase in cardiovascular complications with the higher dose carfilzomib?

How do experts view the clinical hold on CheckMate-602, CheckMate-039 and CA204142?

Is there a future for PD-1/PD-L1-based combinations in multiple myeloma?

What do experts expect from BioLineRx's Phase III GENESIS trial for BL-8040?

How do KOLs perceive BL-8040 potential for the mobilization of hematopoietic stem cells for autologous transplantation in patients?

Could BL-8040 replace Sanofi's plerixafor (Mozobil) and become the new standard of care?

Additional Details

Publisher : FirstWord Pharma
Reference :
Number of Pages : 0
Report Format : PDF
Publisher Information :


FirstWord
BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data
BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data
Best Prices
Guaranteed
bioportfolio.co.uk

Table Of Contents for Multiple Myeloma: Update Bulletin #2 [Report Updated: 01-12-2017]

How to Buy...

Multiple Myeloma: Update Bulletin #2 [Report Updated: 01-12-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

https://www.bioportfolio.co.uk/product/197052

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk
or **Fax** it to us at +44 (0)1305 791844.We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: .....

Job Title: .....

Your Email: .....

Your Contact Phone: .....

Company Name: .....

Address: .....

.....

Post/Zip Code: .....

Country: .....

P.O. Number: .....

Any Other Instructions: .....

.....

Pricing Options: (please tick one)
○ **$1095** | Single User Price
○ **$2675** | Global License Price

Payment Options: (please tick one)
○ **Online Credit Card** (we will email you the invoice with a payment link)
○ **Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature: .....

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.